These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 27650354)
1. Dual Signal Amplification Electrochemical Biosensor for Monitoring the Activity and Inhibition of the Alzheimer's Related Protease β-Secretase. Qu F; Yang M; Rasooly A Anal Chem; 2016 Nov; 88(21):10559-10565. PubMed ID: 27650354 [TBL] [Abstract][Full Text] [Related]
2. Amplified voltammetric characterization of cleavage of the biotinylated peptide by BACE1 and screening of BACE1 inhibitors. Yi X; Han H; Zhang Y; Wang J; Zhang Y; Zhou F Biosens Bioelectron; 2013 Dec; 50():224-8. PubMed ID: 23867352 [TBL] [Abstract][Full Text] [Related]
3. Electrochemiluminescence and electrochemical dual-mode detection of BACE1 activity based on the assembly of peptide and luminol co-functionalized silver nanoparticles induced by cucurbit[8]uril. Wei X; Fan J; Hao Y; Dong H; Zhang Y; Zhou Y; Xu M Talanta; 2024 Jan; 266(Pt 1):124904. PubMed ID: 37473471 [TBL] [Abstract][Full Text] [Related]
4. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo. Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692 [TBL] [Abstract][Full Text] [Related]
5. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745 [TBL] [Abstract][Full Text] [Related]
7. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622 [TBL] [Abstract][Full Text] [Related]
8. A single electrochemical biosensor for detecting the activity and inhibition of both protein kinase and alkaline phosphatase based on phosphate ions induced deposition of redox precipitates. Shen C; Li X; Rasooly A; Guo L; Zhang K; Yang M Biosens Bioelectron; 2016 Nov; 85():220-225. PubMed ID: 27179562 [TBL] [Abstract][Full Text] [Related]
9. BACE1: the beta-secretase enzyme in Alzheimer's disease. Vassar R J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696 [TBL] [Abstract][Full Text] [Related]
10. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Moussa CE Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311 [TBL] [Abstract][Full Text] [Related]
11. A Novel Dual Fluorochrome Near-Infrared Imaging Probe for Potential Alzheimer's Enzyme Biomarkers-BACE1 and Cathepsin D. Tam JM; Josephson L; Pilozzi AR; Huang X Molecules; 2020 Jan; 25(2):. PubMed ID: 31936569 [TBL] [Abstract][Full Text] [Related]
12. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels. Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548 [TBL] [Abstract][Full Text] [Related]
13. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. Vassar R J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664 [TBL] [Abstract][Full Text] [Related]
15. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS. Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639 [TBL] [Abstract][Full Text] [Related]
16. A microfluidics-based mobility shift assay to identify new inhibitors of β-secretase for Alzheimer's disease. Liu R; Liu YC; Meng J; Zhu H; Zhang X Anal Bioanal Chem; 2017 Nov; 409(28):6635-6642. PubMed ID: 28889204 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model. Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367 [TBL] [Abstract][Full Text] [Related]
18. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease. Barão S; Moechars D; Lichtenthaler SF; De Strooper B Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257 [TBL] [Abstract][Full Text] [Related]
19. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464 [TBL] [Abstract][Full Text] [Related]